- Home
- ETY vs NEO Comparison
ETY vs NEO Comparison
Compare ETY & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ETY | NEO |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2005 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ETY | NEO |
|---|---|---|
| Price | $13.67 | $17.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $23.33 |
| AVG Volume (30 Days) | 310.6K | ★ 2.1M |
| Earning Date | 01-01-0001 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.12 |
| Revenue Next Year | N/A | $9.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.12 | $7.07 |
| 52 Week High | $15.90 | $20.15 |
Technical Indicators
Market Signals| Indicator | ETY | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 49.68 |
| Support Level | $13.12 | $16.87 |
| Resistance Level | $14.79 | $19.99 |
| Average True Range (ATR) | 0.16 | 0.84 |
| MACD | -0.02 | 0.13 |
| Stochastic Oscillator | 7.89 | 57.15 |
Price Performance
Historical ComparisonAbout ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.